Neurological Sciences

, Volume 39, Issue 12, pp 2135–2139 | Cite as

Serum NT-pro CNP levels in epileptic seizure, psychogenic non-epileptic seizure, and healthy subjects

  • Mustafa CeylanEmail author
  • Ahmet Yalcin
  • Omer Faruk Bayraktutan
  • Esra Laloglu
Original Article



Epileptic seizure is the result of uncontrollable neural excitation in the brain. The C-type natriuretic peptide is a member of natriuretic peptide hormone family and is synthesized by brain and blood vessels in CNS. NT-pro CNP is an amino-terminal fragment of C-type natriuretic peptide and is more stable compared to its predecessor. In this study, we aimed to evaluate the role of NT-pro CNP in psychogenic non-epileptic seizures, epileptic seizures, and normal subjects.


Thirty-three patients with epilepsy and 43 patients with psychogenic non-epileptic seizures were enrolled in this study. The control group consisted of 28 healthy subjects. Post-ictal serum levels of NT-pro CNP were acquired from all participants. Statistically significant differences between patient groups and controls regarding serum levels of NT-pro CNP were sought.


NT-pro CNP levels were significantly lower in the epilepsy group than the psychogenic non-epileptic seizure group and control group with no significant difference between the psychogenic non-epileptic seizure and control group (p < 0.05).


Post-ictal serum NT-pro CNP levels were lower in epileptic seizures compared to psychogenic non-epileptic seizures as well as healthy controls. We think that such a difference is associated with C-type natriuretic peptide-related neural mechanisms such as altered microcirculation, increased brain-blood barrier permeability, and synaptic stabilization.


Epilepsy Psychogenic non-epileptic seizure NT-pro CNP Biomarker 


  1. 1.
    Bodde NMG, Brooks JL, Baker GA, Boon PAJM, Hendriksen JGM, Mulder OG, Aldenkamp AP (2009) Psychogenic non-epileptic seizures--definition, etiology, treatment and prognostic issues: a critical review. Seizure 18:543–553CrossRefPubMedGoogle Scholar
  2. 2.
    Noachtar S, Peters AS (2009) Semiology of epileptic seizures: a critical review. Epilepsy Behav 15:2–9CrossRefPubMedGoogle Scholar
  3. 3.
    Alsaadi TM, Thieman C, Shatzel A et al (2004) Video-EEG telemetry can be a crucial tool for neurologists experienced in epilepsy when diagnosing seizure disorders. Seizure 13:32–34CrossRefPubMedGoogle Scholar
  4. 4.
    Dobesberger J, Walser G, Unterberger I, Seppi K, Kuchukhidze G, Larch J, Bauer G, Bodner T, Falkenstetter T, Ortler M, Luef G, Trinka E (2011) Video-EEG monitoring: safety and adverse events in 507 consecutive patients. Epilepsia 52:443–452CrossRefPubMedGoogle Scholar
  5. 5.
    Lukasiuk K, Becker AJ (2014) Molecular biomarkers of epileptogenesis. Neurotherapeutics 11:319–323CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Dash PK, Zhao J, Hergenroeder G, Moore AN (2010) Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics 7:100–114CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Glushakova OY, Jeromin A, Martinez J, Johnson D, Denslow N, Streeter J, Hayes RL, Mondello S (2012) Cerebrospinal fluid protein biomarker panel for assessment of neurotoxicity induced by kainic acid in rats. Toxicol Sci 130:158–167CrossRefPubMedGoogle Scholar
  8. 8.
    Scotland RS, Ahluwalia A, Hobbs AJ (2005) C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther 105:85–93CrossRefPubMedGoogle Scholar
  9. 9.
    Stingo AJ, Clavell AL, Heublein DM et al (1992) Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Phys 263:1318–1321Google Scholar
  10. 10.
    Nishikimi T, Kuwahara K, Nakao K (2011) Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 57:131–140CrossRefPubMedGoogle Scholar
  11. 11.
    Komarek M, Bernheim A, Schindler R, Steden R, Kiowski W, Rocca HPBL (2004) Vascular effects of natriuretic peptides in healthy men. J Cardiovasc Pharmacol Ther 9:263–270CrossRefPubMedGoogle Scholar
  12. 12.
    Brandt RR, Mattingly MT, Clavell AL, Barclay PL, Burnett JC (1997) Neutral endopeptidase regulates C-type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo. Hypertension 30:184–190CrossRefPubMedGoogle Scholar
  13. 13.
    Schouten BJ, Prickett TC, Hooper AA et al (2011) Central and peripheral forms of C-type natriuretic peptide (CNP): evidence for differential regulation in plasma and cerebrospinal fluid. Peptides 32:797–804CrossRefPubMedGoogle Scholar
  14. 14.
    Prickett TCR, Yandle TG, Nicholls MG, Espiner EA, Richards AM (2001) Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem Biophys Res Commun 286:513–517CrossRefPubMedGoogle Scholar
  15. 15.
    Chen DK, So YT, Fisher RS (2005) Use of serum prolactin in diagnosing epileptic seizures: report of the therapeutics and technology assessment Subcommittee of the American Academy of Neurology. Neurology 65:668–675CrossRefPubMedGoogle Scholar
  16. 16.
    Chang CC, Lui CC, Lee CC et al (2012) Clinical significance of serological biomarkers and neuropsychological performances in patients with temporal lobe epilepsy. BMC Neurol 14:12–15Google Scholar
  17. 17.
    Anand-Srivastava MB (2005 Jun) Natriuretic peptide receptor-C signaling and regulation. Peptides 26(6):1044–1059 ReviewGoogle Scholar
  18. 18.
    Hu P, Zhao XQ, Wang J, Kong HB, Hu B, Lu L, Qin YH (2014) Paradoxical expressions of natriuretic peptide receptor-C and neutral endopeptidase account for C-type natriuretic peptide decline during the progression of experimental obstructive nephropathy. J Renin-Angiotensin-Aldosterone Syst 15:458–465CrossRefPubMedGoogle Scholar
  19. 19.
    Peebles KC, Richards AM, Celi L, Mc Grattan K, Murrell CJ, Ainslie PN (2008) Human cerebral arteriovenous vasoactive exchange during alterations in arterial blood gases. J Appl Physiol 105:1060–1068CrossRefPubMedGoogle Scholar
  20. 20.
    Prickett TC, Charles CJ, Yandle TG, Richards AM, Espiner EA (2009) Skeletal contributions to plasma CNP forms: evidence from regional sampling in growing lambs. Peptides 30:2343–2347CrossRefPubMedGoogle Scholar
  21. 21.
    Van Paesschen W (2004) Ictal SPECT. Epilepsia 45:35–40CrossRefPubMedGoogle Scholar
  22. 22.
    Boscolo Galazzo I, Storti SF, Del Felice A et al (2015) Patient-specific detection of cerebral blood flow alterations as assessed by arterial spin labeling in drug-resistant epileptic patients. PLoS One 6:10Google Scholar
  23. 23.
    Attwell D, Buchan AM, Charpak S, Lauritzen M, MacVicar BA, Newman EA (2010) Glial and neuronal control of brain blood flow. Nature 468:232–243CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Bohara M, Kambe Y, Nagayama T, Tokimura H, Arita K, Miyata A (2014) C-type natriuretic peptide modulates permeability of the blood-brain barrier. J Cereb Blood Flow Metab 34:589–596CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Muller D, Hida B, Guidone G et al (2009) Expression of guanylyl cyclase (GC)-A and GC-B during brain development: evidence for a role of GC-B in perinatal neurogenesis. Endocrinology 150:5520–5529CrossRefPubMedGoogle Scholar
  26. 26.
    Decker JM, Wojtowicz AM, Bartsch JC et al (2010) C-type natriuretic peptide modulates bidirectional plasticity in hippocampal area CA1 in vitro. Neuroscience 169:8–22CrossRefPubMedGoogle Scholar
  27. 27.
    Zhao Z, Ma L (2009) Regulation of axonal development by natriuretic peptide hormones. Proc Natl Acad Sci U S A 106:18016–18021CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Faculty of Medicine, Department of NeurologyAtaturk UniversityErzurumTurkey
  2. 2.Faculty of Medicine, Department of RadiologyErzincan UniversityErzincanTurkey
  3. 3.Section of NeurologyRegional Education and Research HospitalErzurumTurkey
  4. 4.Department of BiochemistryErzurum Public Health LaboratoryErzurumTurkey

Personalised recommendations